What the research found

This perspective paper reviews existing evidence on physical activity and protein intake, arguing that current UK health guidelines set thresholds merely to prevent deficiency rather than to optimise health. The author contends that government recommendations lag behind what the literature suggests is needed for maintaining strength, independence, and cognitive function across the lifespan.

On activity, the evidence points in one direction: more movement correlates with lower mortality risk, with benefits observable even at modest volumes (around 15 minutes daily) and continuing to improve with greater duration and intensity. Critically, the dose matters by type—both aerobic work and resistance training appear necessary, with muscular strength showing particularly strong associations with longevity and independence. On protein, the current UK recommendation of 0.34 g/lb/day targets sedentary maintenance; the author flags that research in resistance-trained individuals, older adults, and pregnant women suggests substantially higher intakes yield measurable benefits for muscle composition, function, and pregnancy outcomes.

Why it matters for you

If you're already tracking training volume and adjusting protein intake around your protocol, this framing validates that instinct. Most MyKine users engaging in resistance training likely consume well above government minimums—the paper suggests 1 g/lb/day aligns with optimal outcomes for that population, a figure many of you already target. The muscular strength data is worth noting: the paper cites a ~200% elevation in mortality risk for low versus high strength, dwarfing the ~50% risk from smoking. That reframes resistance training not as aesthetic or performance optimisation, but as a primary health intervention.

For biomarkers you track, higher protein intake and progressive resistance training directly influence muscle mass, bone density, and inflammatory markers. The dual emphasis on both aerobic and resistance work suggests your programming should include both modalities, not favour one. If you're over 50, the case for doubling current protein recommendations becomes stronger—sarcopenia is one of the few "diseases of aging" with clear, dose-responsive countermeasures.

Caveats

• Perspective paper, not original research: This is a narrative review and argument for guideline reform, not a new controlled trial
• Heterogeneous evidence base: Cited studies vary widely in design, population, and quality; some likely observational
• Nutrition evidence particularly weak: The author explicitly notes heavy reliance on self-reported dietary data and calls for better-designed studies
• No effect sizes provided: Claims about optimal protein intake (e.g., 1 g/lb/day) cite research but exact magnitude of benefit and confidence intervals are not detailed here
• UK-specific context: Recommendations are calibrated to current UK guidance; other jurisdictions may differ